Research Study for those with NASH/Fatty Liver Disease

IRB/UVA Tracking #
Principal Investigator
Stephen H Caldwell
Jennifer Greene
Contact Email
Contact Phone
Official Trial Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis
Study Description

The Hepatology Department seeks adults over 18 with PSC (primary sclerosing cholangitis) for a research study. The purpose of the study is see if a medication called GS-9674 safe and effective in treating PSC.

You may be eligible for this study if you have PSC, meet certain lab criteria and can have a MRI and a liver biopsy.

Study involves taking an experimental study medication by mouth daily, having a liver biopsy at the beginning of the study and after two years of treatment and having an MRI at the beginning of treatment. Study lasts up to 2 years. You can participate if you have inflammatory bowel disease (IBD) as well.

Study-related exams, tests and experimental medication provided free of charge.


You will be paid $75 for each visit that you complete.